AlloVir (ALVR) AI Stock Analysis

• Market Cap: $30.20M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: 72.12%
• Country: US
• Employees: 112
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -11.75
• Shares Outstanding: 5,043,357
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: -0.32
• Price to Book (P/B): 9.81
• Price to Sales (P/S): N/A
• P/FCF Ratio: -0.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

AlloVir's overall stock score is primarily constrained by its challenging financial performance, characterized by ongoing losses and lack of revenue. The recent merger with Kalaris Therapeutics offers a positive outlook due to the cash infusion and potential for strategic growth. However, the technical indicators show neutral momentum, and the valuation is weak due to the absence of earnings. These factors collectively result in a below-average stock score.

AlloVir Business Overview & Revenue Model

Company Description

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

How the Company Makes Money

AlloVir makes money primarily through the development and commercialization of its proprietary T cell therapies. The company's revenue model focuses on the successful progression of its clinical trials and eventual regulatory approval, allowing for the marketing and sale of its therapies. Key revenue streams include potential milestone payments and royalties from partnerships with pharmaceutical companies and healthcare providers. AlloVir's earnings are significantly influenced by its ability to advance its clinical pipeline and secure strategic collaborations to support its research and development efforts.

AlloVir Financial Statement Overview

Summary

AlloVir faces significant financial challenges typical of biotech firms in the development phase. The absence of revenue underscores reliance on external funding to sustain operations. While the company has managed to maintain a strong cash position, the ongoing net losses and negative cash flows highlight the need for breakthroughs in product development or revenue generation to achieve financial sustainability.

Income Statement

AlloVir's income statement shows consistent challenges with revenue generation, as the company reported no revenue in the latest periods. This has led to substantial net losses, reflecting the ongoing high costs without offsetting income. The company’s EBIT and EBITDA margins are negative, indicating a significant challenge in managing operational expenses efficiently.

Balance Sheet

The balance sheet reflects a relatively strong equity position with no debt as of the latest report, which is positive. However, the consistent net losses have eroded equity over time. The company’s equity ratio is relatively healthy, indicating a strong reliance on equity financing rather than debt, which reduces financial risk in the near term.

Cash Flow

AlloVir's cash flow statement highlights significant operational cash outflows, reflecting the ongoing operational costs without revenue support. The free cash flow is negative, indicating reliance on external financing or cash reserves for sustainability. However, cash flow from financing activities has helped bolster cash reserves.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-398.00K	-2.56M	-1.12M	-73.00K
EBITDA	-65.44M	-190.15M	-166.41M	-169.84M	-69.71M
Net Income	-58.77M	-190.42M	-168.71M	-171.96M	-68.38M
Balance Sheet
Total Assets	118.55M	190.80M	277.08M	286.59M	370.82M
Cash, Cash Equivalents and Short-Term Investments	118.29M	183.94M	233.79M	248.12M	356.32M
Total Debt	0.00	27.43M	35.39M	30.07M	8.69M
Total Liabilities	5.24M	45.02M	52.56M	61.33M	17.76M
Stockholders Equity	113.31M	145.78M	224.52M	225.27M	353.06M
Cash Flow
Free Cash Flow	-67.70M	-124.45M	-141.95M	-106.34M	-61.05M
Operating Cash Flow	-67.70M	-124.45M	-142.05M	-106.32M	-60.81M
Investing Cash Flow	95.00M	37.98M	-80.48M	185.98M	-169.50M
Financing Cash Flow	21.00K	70.50M	126.96M	232.00K	291.98M

AlloVir Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$17.39B	5.75	-7.44%	3.10%	11.55%	-28.15%
IOVA	57 Neutral	$1.05B	―	-51.85%	―	11070.12%	32.07%
BLUE	51 Neutral	$48.67M	―	-546.55%	―	127.51%	56.94%
SGMO	49 Neutral	$143.71M	―	-262.12%	―	239.92%	79.41%
FATE	46 Neutral	$142.14M	―	-49.23%	―	105.85%	22.13%
ALVR	41 Neutral	$30.20M	―	-45.37%	―	―	72.12%
ADAP	40 Neutral	$89.45M	―	-273.36%	―	883.05%	62.93%

AlloVir Corporate Events

AlloVir Merges with Kalaris Therapeutics, Inc.

On March 18, 2025, Kalaris Therapeutics, Inc. announced the completion of its merger with AlloVir, Inc., resulting in a combined company that will operate under the name Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker symbol ‘KLRS’ starting March 19, 2025. The merger has led to a change in the company’s stock ownership structure, with Legacy Kalaris stockholders owning approximately 74.47% and AlloVir stockholders owning about 25.53% of the combined company’s outstanding common stock. The merger is expected to provide Kalaris with approximately $100 million in cash, which will fund its operations into the fourth quarter of 2026, supporting the continued development of its lead product candidate, TH103, which is currently in a Phase 1 clinical trial.

AlloVir Stockholders Approve Key Amendment and Merger

On March 12, 2025, AlloVir held a special meeting where stockholders approved an amendment to the 2020 Stock Option and Grant Plan, increasing the number of shares available for future issuance and extending the plan’s term. The approval of this amendment and the merger with Kalaris, which involves a change of control and issuance of new shares, is expected to impact AlloVir’s operations by expanding its capital base and potentially enhancing its market position, although there are inherent risks and uncertainties associated with the merger.

AlloVir Appoints Vikas Sinha as New CEO

AlloVir, Inc. announced that Dr. Diana Brainard has stepped down as Chief Executive Officer and director, with Vikas Sinha taking over as CEO effective December 19, 2024. Sinha, who has extensive experience in executive finance roles within the life sciences industry, is expected to lead the company following the departure of Dr. Brainard, who left with a comprehensive severance package.